Thymosin as a possible therapeutic drug for COVID-19: A case report.

Background: There are no effective antiviral therapies for coronavirus disease 2019 (COVID-19) at present. Although most patients with COVID-19 have a mild or moderate course of disease, up to 5%-10% of patients may have a serious and potentially life-threatening condition, indicating an urgent need for effective therapeutic drugs. The therapeutic effect of thymosin on COVID-19 has not been previously studied.

Prediction of the Rehabilitation Duration and Risk Management for Mild-Moderate COVID-19.

Objectives: More than 80% of coronavirus disease 2019 (COVID-19) cases are mild or moderate. In this study, a risk model was developed for predicting rehabilitation duration (the time from hospital admission to discharge) of the mild-moderate COVID-19 cases and was used to conduct refined risk management for different risk populations.

Methods: A total of 90 consecutive patients with mild-moderate COVID-19 were enrolled.